NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DC-22-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact.
Funding Opportunity RFA-DK-21-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D) to avoid acute complications at diagnosis and to allow earlier interventions to prevent and/or delay clinical manifestations and long term complications of the disease.
Notice NOT-AI-21-057 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-018 from the NIH Guide for Grants and Contracts
Notice NOT-AA-21-029 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-275 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.
Funding Opportunity RFA-CA-21-026 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) is publishing this Funding Opportunity Announcement (FOA) to request applications for the Program on the Origins of Gastroesophageal Cancers (R01). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level. The program will address the complex mechanisms and effectors that direct the proliferation and expansion of tumor-initiating cells and their progeny to initiate these cancers. The focus of the FOA is on gastric and gastroesophageal junction adenocarcinomas. The program is envisioned to provide unprecedented opportunities to outline the earliest cellular changes in transformation that precede any histological manifestations or neoplasia. This new program will be composed of up to six large R01 research grants (to be supported by this FOA) and one Coordinating Center grant (to be supported by the companion FOA, RFA-CA-21-027).
Funding Opportunity RFA-CA-21-027 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) is publishing this Funding Opportunity Announcement (FOA) to request applications for the Coordinating Center, Program on the Origins of Gastroesophageal Cancers (U24). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level. The program will address the complex mechanisms and effectors that direct the proliferation and expansion of tumor-initiating cells and their progeny to initiate these cancers. The focus of the FOA is on gastric and gastroesophageal junction adenocarcinomas. The program is envisioned to provide unprecedented opportunities to outline the earliest cellular changes in transformation that precede any histological manifestations or neoplasia. This new program will be composed of up to six large R01 research grants (to be supported by RFA-CA-21-026) and one Coordinating Center grant (to be supported by this FOA).
Notice NOT-CA-21-091 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-21-266 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the creation and utilization of Patient Safety Learning Laboratories (PSLL). These learning laboratories are places and networks where transdisciplinary teams identify closely related threats to diagnostic or treatment efforts associated with a high burden of harm and cost. Following a systems engineering methodology, the learning laboratories stretch professional boundaries, envision innovative designs, and take advantage of brainstorming and rapid prototyping techniques that other leading industries employ. Promising prototypes undergo further develop-test-revise iterations, and subsequent integration as a working system. After further improvements are made to the integrated working system, its efficacy is evaluated in a realistic simulated or clinical setting.
Notice NOT-CA-21-090 from the NIH Guide for Grants and Contracts
Notice NOT-HG-21-032 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-21-040 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for U54 Research Centers to form the Radiation Oncology-Biology Integration Network (ROBIN). The cadre of ROBIN Centers created through this FOA will establish an agile and effective national radiation oncology network infrastructure that collectively address critical hypothesis-based translational research knowledge gaps on the biological basis of responses in cancer patients who undergo radiation treatments.
Notice NOT-MH-21-270 from the NIH Guide for Grants and Contracts
Notice NOT-DE-21-005 from the NIH Guide for Grants and Contracts
Notice NOT-NS-21-066 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-22-003 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse [NIDA] seeks research proposals to identify the effects of anti-retroviral therapy (ART) used for the treatment of HIV/AIDS on neuronal and glial structure and function, particularly when occurring in a background of chronic exposure to an abused drug (including opioids, cocaine and stimulants, cannabinoids, and nicotine). The overall goal is to determine the contributions of antiretroviral [ARV] treatment regimens that are used to suppress viral load in the neurological and neurocognitive deficits that are associated with HIV-Associated Neurocognitive Disorders [HAND].
Funding Opportunity RFA-AG-22-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that propose to add enhanced measures of educational experiences, cognitive function, or both to existing studies and/or to conduct analyses that incorporate these measures to clarify the relationship between education, cognition, and risk of Alzheimers disease and Alzheimers disease-related dementias (AD/ADRD), including the role of education in social disparities in AD/ADRD outcomes.
Notice NOT-CA-21-083 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-250 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial optional, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase.